Cargando…
Ever closer to a prophylactic vaccine for HCV
INTRODUCTION: With 3 – 4 million new infections occurring annually, hepatitis C virus (HCV) is a major global health problem. There is increasing evidence to suggest that HCV will be highly amenable to a vaccine approach, and despite advances in treatment, a vaccine remains the most cost-effective a...
Autores principales: | Swadling, Leo, Klenerman, Paul, Barnes, Eleanor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa UK, Ltd.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741017/ https://www.ncbi.nlm.nih.gov/pubmed/23651228 http://dx.doi.org/10.1517/14712598.2013.791277 |
Ejemplares similares
-
Cross‐reactivity of hepatitis C virus specific vaccine‐induced T cells at immunodominant epitopes
por: Kelly, Christabel, et al.
Publicado: (2014) -
Hepatic encephalopathy: Ever closer to its big bang
por: Souto, Pablo A, et al.
Publicado: (2016) -
Six Feet Apart, yet Closer than Ever
por: Gennie Wang, Jing
Publicado: (2020) -
Polymer and small molecule mechanochemistry: closer than ever
por: Hernández, José G
Publicado: (2022) -
Therapeutic vaccines in HBV: lessons from HCV
por: Barnes, Eleanor
Publicado: (2015)